Perrigo Updates Segment Reporting Structure

Perrigo Company has changed its reporting segments to better align with the Company's organizational structure. Beginning with the fourth quarter of calendar year 2016, the company's new reporting segments are:

Consumer Healthcare Americas – Comprises the legacy U.S., Mexico and Canada consumer healthcare business (OTC, contract, infant formula and animal health categories).

Consumer Healthcare International – Comprises the legacy Branded Consumer Healthcare segment and now includes our consumer focused businesses in the U.K, Australia and Israel, which were previously reported in the legacy Consumer Healthcare segment. This segment will also include our U.K. liquids licensed products business, which was previously reported in the Prescription Pharmaceuticals segment.

Prescription Pharmaceuticals – Comprises the legacy U.S. Prescription Pharmaceuticals business.

Specialty Sciences – Will continue to comprise royalties from Tysabri®.

Other – Will continue to comprise the legacy Active Pharmaceutical Ingredients (API) business.

The changes to the reporting segments have no impact on the Company's historical consolidated financial position, results of operations, or cash flows. In order to aid in comparability to historical financial data, the Company has recast selected financial statements and metrics utilizing the new reporting segments. A current report on Form 8-K containing recast quarterly and annual information for calendar years 2016, 2015, 2014 and 2013 will be issued today.